Unfarnesylated transforming Ras mutant inhibits the Ras-signaling pathway by forming a stable Ras·Raf complex in the cytosol  by Miyake, Mika et al.
FEBS 16487 FEBS Letters 378 (1996) 15-18 
Unfarnesylated transforming Ras mutant inhibits the Ras-signaling 
pathway by forming a stable RasaRaf complex in the cytosol 
Mika Miyake, Shin Mizutani, Hiroshi Koide, Yoshito Kaziro* 
Faculty qf Bioscience and Biotechnology, Tokyo Institute qf Technology, 4259 Nagatsuta, Midori-ku, Yokohama 226, Japan 
Received 16 November 1995; revised version received 23 November 1995 
Abstract Farnesyltransferase inhibitors cause the growth arrest 
of rus-transformed cells, but not that of normal cells. To elucidate 
the mechanism of this differential effect, we examined the effect 
of accumulation of unfarnesylated Ras in the cytosol by using 
RasGrzv~crsss and RasC’86S, which mimic unfarnesylated form of 
the oncogenic and the normal Ras, respectively. We found that 
RasC12,C186s inhibited activation and membrane translocation of 
Raf by forming a stable complex with Raf in the cytosol. In 
contrast, RasC’86S showed inhibitory effect on neither Raf activa- 
tion nor Raf translocation. These results indicate that unfarnesyl- 
ated oncogenic Ras interacts with Raf in the cytosol and inhibits 
its membrane translocation, a crucial step for the Raf activation, 
while unfarnesylated normal Ras does not. 
Key words: Ras; Farnesylation; Dominant-negative mutant; 
Raf 
1. Introduction 
Ras belongs to a family of low-molecular-weight GTP-bind- 
ing proteins and functions in the regulation of cellular prolifer- 
ation, differentiation, and transformation [l-3]. Ras cycles be- 
tween two forms, an active GTP-bound form (Ras’GTP) and 
an inactive GDP-bound form (Ras’GDP). Ras is localized to 
the cytoplasmic membrane and this is facilitated by a series of 
posttranslational modification occurring at the C-terminus 
[4,5]. In the case of Ha-Ras, the modification is triggered by 
farnesylation of Cys-186, followed by proteolytic removal of 
the C-terminal three amino acids, carboxyl methylation of Cys- 
186 and palmitoylation of Cys- 18 1 and Cys- 184. Substitution 
of Cys-186 with other amino acids results in a mutant protein 
which is completely blocked in processing, localized in the cy- 
tosol, and devoid of the transforming activity 161. 
The importance of the farnesylation of Ras to its transform- 
ing function has raised a possibility that farnesyltransferase 
inhibitors may act as anticancer drugs [7,8], since oncogenic 
mutations of ras gene are found in a wide variety of human 
tumors [1,9]. Recently, several groups have succeeded in the 
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isolation of farnesyltransferase inhibitors which induce growth 
arrest of ras-transformed cells [ 10,111. Interestingly, these in- 
hibitors showed a differential effect on the growth of normal 
and transforming cells. At the concentration which causes the 
growth arrest of rus-transformed cells, the inhibitors had no 
effect on the growth of normal cells [ 11,121. Moreover, detailed 
analyses have revealed that the reversion of the ras-transformed 
cells occurs prior to the complete inhibition of processing of 
Ras [12,13]. Thus, it is unlikely that the observed growth arrest 
was caused by the depletion of the farnesylated Ras. Previous 
reports indicated that mutants of oncogenic Ras defective in 
targeting to membrane, function as dominant-negative mutants 
[ 14171, suggesting that unfarnesylated oncogenic Ras may in- 
hibit the Ras-signaling pathways. 
It has been shown that Ras’GTP interacts directly with Raf 
[I S-221, which is a cytosolic serine/threonine kinase involved in 
the activation of the mitogen-activated protein kinases 
(MAPKs) [23,24]. After interaction with Ras GTP, Raf is acti- 
vated by a still unknown mechanism [25]. The activated Raf 
then phosphorylates and activates MAPK kinase (MEK), 
which in turn activates MAPK by phosphorylation on tyrosine 
and serine/threonine residues [26,27]. Though the precise role 
of Ras in Raf activation remains still ambiguous, recent reports 
have revealed that Ras-mediated Raf translocation from cy- 
tosol to membrane is a prerequisite for the activation of Raf 
[28,29]. 
We assume that treatment of ras-transformed cells with far- 
nesyltransferase inhibitors may result in accumulation of unfar- 
nesylated form of oncogenic Ras, which sequesters Raf in the 
cytosolic fraction. On the other hand, unfarnesylated wild-type 
Ras which accumulates in the GDP-bound form does not inter- 
act with Raf. To assess this hypothesis, we examined the effect 
of accumulation of unfarnesylated oncogenic Ras on Ras-medi- 
ated Raf activation. In the present study, we constructed two 
Ha-Ras mutants, Rasc’2Yc’shs (Vl2Ras-SVLS) and RasC’86S 
(G12Ras-SVLS), which fail to undergo farnesylation because 
of the C186S substitution and thus mimic unfarnesylated form 
of oncogenic and normal Ras, respectively. Using these two 
mutants, we have shown that V12Ras-SVLS functions as a 
dominant-negative mutant to inhibit Ras-induced activation of 
Raf as well as that of MAPK. Expression of V12Ras-SVLS 
resulted in the inhibition of Ras-induced membrane transloca- 
tion of Raf. In the cytosol, V12Ras-SVLS accumulated in the 
GTP-bound form to form a stable complex with Raf. In con- 
trast, G12Ras-SVLS which accumulates in the GDP-bound 
form failed to interact with Raf and did not affect the activation 
and translocation of Raf. These results indicate that unfarnesyl- 
ated oncogenic Ras inhibits Ras-induced Raf activation by 
preventing the translocation of Raf to membrane, while unfar- 
nesylated normal Ras does not. 
All rights reserved. 
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2. Materials and methods 
2.1. Materials 
Antibodies against Raf-1 (C-20) and Ha-Ras (C-20) were obtained 
from Santa Cruz Biotechnology. Antibodies against MAPK (#05--l 57). 
flag epitope (M2), and Ha-Ras (LA069) were purchased from Upstate 
Biotechnology, Eastman Kodak and Quality Biotech, respectively. Re- 
combinant histidine-tagged Xrnopus MEK [30] and glutathione-S- 
transferase (GST)-fused kinase-deficient Xenopus MAPK [31] were 
produced using bacterial expression systems (kindly given by E. 
Nishida and Y. Gotoh, Kyoto University, Japan) and purified as de- 
scribed in [30,31]. Complementary DNAs of V12Ras-CVLS and 
V12Ras-SVLS were kindly provided by P. Kirshmeier (Schering- 
Plough Research Institute, NJ). 
2.2. Plasmid DNAs 
To make GI2Ras-SVLS, we substituted Val” of VlZRas-SVLS with 
Gly by oligonucleotide-directed mutagenesis. The mutation was con- 
firmed by dideoxynucleotide sequencing. The cDNAs of 
RasG’2v(V12Ras-CVLS), V12Ras-CVLS, G12Ras-SVLS and Vl?Ras- 
SVLS were subcloned into the EcoRI-Hind111 site of pCMV5 vector 
[32] to generate pCMV-V12RasCVLS, pCMV-GI2RasSVLS and 
pCMV-V12RasSVLS, respectively. For expression of Raf. WC used 
pLNC-Raf-1 :FH6 (a kind gift from M. McMahon, DNAX 
Research Institute, Palo Alto, CA) encoding human c-Raf-I with 
flag-epitope tag and six histidine residues in its C-terminus (Raf- 
FH6). 
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3. Results 
2.3. C<~ll culturr rend transjection 
Human embryonic kidney (HEK) 293 cells were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal bo- 
vine serum (FBS) at 37°C in an atmosphere of 10% CO,/90% air. DNA 
transfection was performed by the calcium phosphate coprecipitation 
method. HEK293 cells were exposed for 1 day to DNA precipitates in 
DMEM containing 10% FBS and then starved for I day in DMEM 
containing 1 mg/ml bovine serum albumin before being used in subse- 
quent experiments. 
2.4. MAP kinase mobility .shift 
Two days after transfection, the cells were harvested, washed twice 
with cold phosphate-buffered saline and lysed in buffer A (20 mM 
Hepes, pH 7.0, 10 mM MgCI,, 1 mM EDTA, 1 mM EGTA. 10 mM 
NaF, 1 mM Na,VO,, 25 mM b-glycerophosphate, 20 pug/ml aprotinin, 
lO~g/ml leupeptin, and lO~g/ml pepstatin A) containing 150 mM KCI, 
10% glycerol and 0.5% Triton X-100. The lysate was boiled in the 
sample buffer for SDS-polyacrylamide gel electrophoresis (SDS- 
PAGE). The boiled sample was fractionated by SDS-PAGE (10%) and 
transferred to a nitrocellulose filter. Western blot analysis was per- 
formed with an anti- MAPK antibody (#05-l 57) using the ECL detec- 
tion system (Amersham). 
2.5. Raf kinase assay 
Raf kinase assay was performed as described in [33]. Briefly, trans- 
fected cells were lysed with buffer A containing 150 mM KCI, 10% 
glycerol and 0.5% Triton X-100 and then endogenous c-Raf-I in the 
lysate was immunoprecipitated with anti-c-Raf-1 antibody (C-20). 
After washing, the precipitate was incubated at 30°C for 20 min with 
0.3 pg of recombinant histidine-tagged MEK, 3.4 pug of recombinant 
GST-fused kinase-deficient MAPK, 0.28 mM ATP and 150 kBq [u- 
“P ATP. The reaction was stopped by boiling in the sample buffer for 1 
SDS-PAGE and the samples were resolved by SDS-PAGE (10%). The 
radioactivity incorporated into the kinase-deficient GST-MAPK was 
detected by autoradiography and measured by an image analyzer 
(FUJI BAS2000). 
2.6. Cell fractionation 
Transfected HEK293 cells were harvested and homogenized in ice- 
cold buffer A containing 250 mM sucrose. The postnuclear supcrnatant 
was centrifuged for 60 min at 100,000 x g yielding the cytoplasmic 
fraction and the membrane pellet. The latter was washed. resuspended 
in buffer A containing 250 mM sucrose and 1% Triton X-100. and 
centrifuged for 10 min at 10,000 x g. The supernatant was saved as the 
membrane fraction. 
3.1. Inhibition qf Ras-mediuted signaling pathway ~JJ 
V12Ra.vSVLS 
First, we examined whether V12Ras-SVLS inhibits the Ras- 
mediated signaling pathway. Transfection of HEK293 cells 
with the Vl2Ras-CVLS expression vector induced a shift in the 
mobility of MAPK, indicating MAPK activation (Fig. IA). 
This shift was inhibited by co-expression of VI 2Ras-SVLS (Fig. 
IA). In contrast, Gl2Ras-SVLS showed a negligible effect on 
the Ras-induced MAPK activation. In these experiments, we 
confirmed by Western blotting with an anti-Ras antibody (C- 
20) that both Vl2Ras-SVLS and G12Ras-SVLS were expressed 
in a dose-dependent manner and existed in the soluble, but not 
in the particulate fraction (data not shown). Next, we examined 
the effect of these mutants on Raf. Measurement of the Ras- 
induced activation of Raf with the in vitro kinase assay revealed 
that Vl2Ras-SVLS inhibited the activation of Raf, while 
Gl2Ras-SVLS did not show any effect (Fig. 1 B). 
3.2. V12Ra.vSVLS inhibits Ras-induced membrane 
trtrnslocation of Raj 
Upon activation, Ras induces translocation of Raf to the 
A 
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Fig. I. Inhibition of the Ras-induced activation of MAP kinase (A) and 
Raf (B) by V12Ras-SVLS. (A) HEK293 cells were transfected with the 
indicated amount of expression vectors. Detergent lysates were resolved 
by SDS-PAGE, transferred to a nitrocellulose membrane and blotted 
with an anti-MAPK antibody. The data are representative of three 
separate experiments. (B) Cells were trdnsfected with 1 pg of pCMV- 
V12RasCVLS and 5 pg of either pCMV-VI2RasSVLS or pCMV- 
Gl2RasSVLS. From the cell lysate, endogenous c-Raf-1 was im- 
munoprecipitated and incubated at 30°C for 20 min with purified re- 
combinant MEK and kinase-deficient MAPK in the presence of [y- 
“P]ATP. The data are expressed as percentage of the 32P incorporated 
into MAPK with V12Ras-CVLS alone and are shown as the 
meanfS.D. from three independent experiments. 
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cytoplasmic membrane. As shown in Fig. 2, expression of 
Vl2Ras-CVLS together with Raf-FH6 resulted in the accumu- 
lation of Raf-FH6 in the membrane fraction, which was re- 
duced by co-expression of Vl2Ras-SVLS, but not Gl2Ras- 
SVLS. The result indicates that Ras-mediated translocation of 
Raf to the cytoplasmic membrane was inhibited by Vl2Ras- 
SVLS. 
3.3. VlZRas-SVLS forms a stable complex with Raf in the 
cytosol 
Vl2Ras-SVLS is deficient in the intrinsic GTPase activity 
and stays in the GTP-bound form. Therefore, it is expected that 
Raf is trapped in the cytosolic fraction by forming a stable 
complex with Vl2Ras-SVLS. We tested the possibility by im- 
munoprecipitation method. The cytosol prepared from the cells 
expressing V12Ras-SVLS and Raf-FH6 was treated with an 
anti-Ras antibody (LA069). After Western blot analysis, we 
detected Raf-FH6 in the immunoprecipitate (Fig. 3), suggesting 
that Vl2RasSVLS formed a stable complex with Raf-FH6 in 
the cytosol. On the other hand, in the case of Gl2Ras-SVLS, 
we did not detect significant amount of Raf-FH6 in the precip- 
itate (Fig. 3), although the amount of Ras in the immunoprecip- 
itate was comparable to that obtained with Vl2Ras-SVLS (data 
not shown). 
4. Discussion 
In this paper, we demonstrate that: (1) V12Ras-SVLS, but 
not G 12Ras-SVLS, inhibits the Ras-mediated signaling path- 
way; (2) expression of Vl2Ras-SVLS inhibits Ras-induced 
translocation of Raf to the cytoplasmic membrane, while ex- 
pression of Gl2Ras-SVLS has no effect; and (3) Vl2Ras-SVLS, 
but not Gl2Ras-SVLS, forms a complex with Raf in the cy- 
tosol. From these results, we conclude that Vl2RasSVLS in- 
hibits Ras-induced Raf activation by sequestering Raf in the 
cytosols. This is supported by the observation that overexpres- 
sion of Raf overcomes the inhibitory effect of Vl2Ras-SVLS 
(data not shown). The mechanism of activation of Raf in the 
cytoplasmic membrane has not yet been fully understood. It 
has been shown that Src, a membrane-bound tyrosine kinase, 
activates Raf synergistically with Ras [34], suggesting that Src 
may be involved in the Ras-induced Raf activation. In consist- 
+ Raf-FH6 
Fig. 2. Inhibition of the Ras-induced translocation of Raf to the cyto- 
plasmic membrane by V12Ras-SVLS. Cells were transfected with 1 ,~.a 
of pCMV-V12RasCVLS. 5 pg of pLNC-Raf- 1: FH6, and 5 fig of either 
pCMV-V12RasSVLS or pCMV-G12RasSVLS. After cell fractiona- 
tion, Raf-FH6 was immunoprecipitated from the membrane fraction 
with antiflag antibody. The precipitate was probed with antiflag anti- 
body to detect Raf-FH6. An arrow indicates the Raf-FH6 band. The 
results shown are the representative of three separate experiments. 
+ Raf-FH6 
Fig. 3. Accumulation of the Ras. Raf complex formation in the cytosol 
induced by RasV12-SVLS. Cells were transfected with 1 pg of pCMV- 
V12RasCVLS 10 pg of pLNC-Raf-l : FH6 and 5 pg of either pCMV- 
Vl2RasSVLS or pCMV-G12RasSVLS. From the cytosolic fraction, 
Ras was immunoprecipitated with an anti-Ras antibody (LA069) and 
Raf-FH6 in the immunoprecipitate was detected by Western blot anal- 
ysis with an antiflag antibody. An arrow indicates the Raf-FH6 band. 
The data are representative of three independent experiments. 
ent with this idea, we observed that Vl2Ras-SVLS also inhibits 
v-Src-induced Raf activation (data not shown). 
The present study demonstrates clearly that Vl2Ras-SVLS, 
which mimics unfdrnesylated oncogenic Ras, blocks the Ras- 
induced Raf activation, while Gl2Ras-SVLS, which mimics 
unfarnesylated normal Ras, showed negligible effect on the Raf 
activation. This corresponds well to the result that the far- 
nesyltransferase inhibitors arrest the growth of ras-transformed 
cells, but not that of normal cells. We consider that the differ- 
ential sensitivity to the farnesyltransferase inhibitors of ras- 
transformed and normal cells is due to the fact that the onco- 
genie Ras accumulates in the cytosols in the GTP-bound con- 
formation, while the normal Ras in the GDP-bound conforma- 
tion. 
Although Vl2RasSVLS inhibits the signal transmission 
from Ras to Raf, it is not known whether this mutant can block 
also the interaction of Ras with other effecters such as RalGDS 
and PI3-kinase [35538]. Recently, Ras has been shown to trans- 
mit the signal, in addition to the Raf-MEK-MAPK pathway, 
to Rat-Rho pathway [3941]. The Rat-Rho pathway is shown 
to be involved in morphological change of transformed cells 
[3942]. Therefore, it would be interesting to see whether 
Vl2Ras-SVLS blocks also this pathway. The isolation and 
characterization of the complex involving Ras and Raf may 
lead to the identification of other molecule(s) contained in the 
complex. The possible candidates are the other Ras-binding 
molecules such as RalGDS and PI3-kinase. and Raf-binding 
proteins such as 14-3-3 [43] and Hsp90 [44]. We hope that this 
kind of analysis may help the further understanding of the 
mechanism of Ras-mediated signal transduction. 
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